Idorsia Enrolls First Patients in US QUVIVIQ Phase 3 Study
The Dari-Dream study targets daytime functioning claims for QUVIVIQ 50 mg, with results expected during 2028.
The Dari-Dream study targets daytime functioning claims for QUVIVIQ 50 mg, with results expected during 2028.